Proposal for Recombinant human Gas6

Overview of Therapeutic Candidate:
Recombinant human Growth arrest‐specific 6 (Gas6) is an endogenous, vitamin K–dependent secreted protein originally discovered as a product of a gene expressed under growth arrest conditions. Gas6 functions naturally as a ligand for the TAM family of receptor tyrosine kinases, which includes Tyro3, Axl, and MerTK. Among these receptors, MerTK is particularly highly expressed in retinal pigment epithelial (RPE) cells, where it plays a central role in initiating and regulating the phagocytosis of photoreceptor outer segments (POS). To balance the immense daily catabolic load in the retina, healthy RPE cells rely on a coordinated process of engulfment and degradation of shed POS that is mediated through activation of MerTK. Recombinant human Gas6, produced using advanced mammalian cell expression systems that preserve critical post‐translational modifications such as vitamin K–dependent gamma‐carboxylation, is designed to recapitulate this natural ligand’s biological activity. As a therapeutic protein, it belongs to the biologics class whose prior applications range from growth factor replacement to immunomodulatory interventions. Its use in dry age-related macular degeneration (AMD) is predicated on its ability to engage MerTK, thereby improving RPE phagocytic function and promoting an anti-inflammatory environment essential for retinal homeostasis (Yefimova et al., 2021, pp. 13–15; Singh, 2013, pp. 37–40).

Therapeutic History:
The Gas6/MerTK axis has garnered robust support from both biochemical and preclinical studies validating its role in maintaining RPE function. Early research demonstrated that RPE cells require functional MerTK for efficient phagocytosis of POS, as evidenced by the Royal College of Surgeons (RCS) rat model of retinal dystrophy, where mutations in MerTK result in a failure to clear shed POS and ultimately lead to retinal degeneration (Yefimova et al., 2021, pp. 3–5). Gene therapy efforts that restore MerTK expression in these models have successfully reestablished phagocytosis and provided photoreceptor protection, thereby underscoring the critical nature of MerTK‐driven signaling in retinal survival. Complementary in vitro studies have revealed that treatment of RPE monolayers with exogenous Gas6 at roughly 200 ng/mL yields a threefold increase in MerTK phosphorylation, which correlates with a 52% improvement in FITC-labeled POS uptake. These quantitative data strongly support the idea that enhancing the Gas6/MerTK pathway can restore phagocytic capacity in RPE cells (Singh, 2013, pp. 37–40). In addition to improving debris clearance, activation of this axis has been shown to induce the production of anti-inflammatory cytokines, such as IL-10, and to initiate signaling cascades that upregulate suppressors of cytokine signaling (SOCS), which help to mitigate chronic inflammatory responses in the retina (Yefimova et al., 2021, pp. 21–23). Although recombinant human Gas6 has not been advanced through extensive clinical trials solely for dry AMD, the broader clinical interest in modulating the TAM receptor pathway is evident from current clinical trial searches investigating Gas6, MerTK, and related proteins in macular degeneration and other retinal degenerative diseases (ClinicalTrials.gov, n.d.; King Khaled Eye Specialist Hospital, 2011).

Mechanism of Action:
At the molecular level, the therapeutic action of recombinant human Gas6 centers on its high-affinity and selective binding to the extracellular domains of TAM receptors, with MerTK being the principal receptor expressed on RPE cells. Upon binding, Gas6 induces receptor dimerization and subsequent auto-phosphorylation of tyrosine residues within the intracellular kinase domain of MerTK. This phosphorylation event triggers a cascade of downstream signals that includes activation of small GTPases, such as Rac1, which facilitates actin cytoskeletal rearrangements necessary for the formation of phagocytic cups. These membrane extensions engulf the POS debris in a process that is integrated with LC3-associated phagocytosis (LAP) mechanisms. In LAP, autophagy-related proteins—including the lipidated form of microtubule-associated protein 1 light chain 3 (LC3)—associate with the phagosomal membrane, expediting its maturation and promoting fusion with lysosomes for effective degradation of the internalized cargo (Yefimova et al., 2021, pp. 6–8). Moreover, MerTK activation by Gas6 initiates anti-inflammatory signaling pathways through phosphorylation of STAT1 and the subsequent upregulation of SOCS1 and SOCS3. These suppressors act by dampening Toll-like receptor (TLR)-mediated pro-inflammatory cascades, thereby shifting the local cytokine milieu toward increased levels of anti-inflammatory cytokines like IL-10 (Yefimova et al., 2021, pp. 13–15, 21–23). Through this dual mechanism—enhancement of LC3-associated phagocytosis and suppression of inflammatory signaling—the Gas6/MerTK pathway works to preserve RPE viability and retinal structure.

Expected Effect:
In the therapeutic setting for dry AMD, the administration of recombinant human Gas6 is expected to produce multiple, synergistic benefits. First, by engaging and activating MerTK receptors on RPE cells, Gas6 is anticipated to significantly boost the efficiency of LC3-associated phagocytosis. This enhanced phagocytic activity will facilitate the prompt and complete clearance of POS debris, thereby preventing toxic accumulations that lead to oxidative stress and secondary inflammation in the subretinal space (Yefimova et al., 2021, pp. 3–5, 6–8). Second, the anti-inflammatory effects derived from Gas6-mediated MerTK activation are expected to modify the cytokine balance in favor of tissue repair and homeostasis. With increased production of anti-inflammatory cytokines like IL-10 and enhanced expression of SOCS proteins, the local immune response in the retina should be dampened, thereby reducing the chronic inflammatory state that accelerates RPE deterioration in dry AMD (Yefimova et al., 2021, pp. 13–15, 23). Furthermore, preclinical animal studies demonstrate that subretinal delivery of Gas6-related therapies in models with defective MerTK signaling, such as the RCS rat, can restore RPE phagocytosis and preserve the photoreceptor layers, suggesting that Gas6 therapy may similarly preserve visual function in human dry AMD (King Khaled Eye Specialist Hospital, 2011). In vitro evidence supporting this hypothesis includes the observation that treatment with recombinant human Gas6 leads to a measurable threefold increase in MerTK phosphorylation, and a corresponding enhancement in POS uptake by more than 50%, markers that directly correlate with improved RPE cell function (Singh, 2013, pp. 37–40). Collectively, the expected outcomes of this therapeutic intervention include a restoration of RPE phagocytic capacity, a reduction in retinal inflammation, and ultimately, preservation of photoreceptor integrity—each of which is critical to slowing or halting the progression of dry AMD.

Overall Evaluation:
Recombinant human Gas6 emerges as a highly compelling candidate for addressing the unmet needs in the treatment of dry AMD, based on its well-characterized mechanism of action, preclinical efficacy, and the clear rationale derived from both genetic and biochemical studies. The strengths of this candidate include the following:

• Mechanistic Validity:
The Gas6/MerTK signaling axis is central to RPE cell biology and has been demonstrated to be essential for the efficient clearance of photoreceptor outer segments. The ability of Gas6 to activate this pathway via receptor dimerization and auto-phosphorylation, thereby stimulating LC3-associated phagocytosis and the cytoskeletal rearrangements needed for debris engulfment, is well established (Yefimova et al., 2021, pp. 6–8). Moreover, the associated anti-inflammatory signaling through STAT1 phosphorylation and SOCS protein induction further supports its therapeutic potential in restoring retinal homeostasis (Yefimova et al., 2021, pp. 13–15).

• Preclinical Efficacy Evidence:
Quantitative in vitro data indicate that treatment with approximately 200 ng/mL recombinant human Gas6 results in a threefold increase in MerTK phosphorylation and a 52% improvement in the uptake of labeled photoreceptor outer segments. These benchmarks provide a solid scientific rationale and measurable efficacy endpoints that are critical for translational research (Singh, 2013, pp. 37–40). In addition, animal model studies, particularly in the RCS rat, have shown that restoring MerTK signaling through approaches that mimic Gas6 action leads to the preservation of photoreceptor layers—a key indicator of potential visual benefit in dry AMD.

• Anti-inflammatory Action:
Given that chronic inflammation exacerbates the progression of dry AMD, the ability of Gas6 to promote the expression of anti-inflammatory cytokines and to suppress Toll-like receptor-driven pro-inflammatory signals is highly advantageous. This dual activity not only addresses the impaired phagocytic function of RPE cells but also modulates the immune environment to prevent further damage (Yefimova et al., 2021, pp. 21–23).

• Genetic and Physiological Validation:
The genetic basis of MerTK dysfunction in retinal degenerative diseases provides a strong foundational rationale for targeting this pathway. The fact that MerTK mutations are directly linked to human conditions such as retinitis pigmentosa underscores the critical role of its signaling axis in retinal integrity (Yefimova et al., 2021, pp. 3–5).

Despite these noteworthy strengths, several challenges remain that must be addressed in the development program:

• Clinical Translation Gap:
While the preclinical and in vitro data are compelling, recombinant human Gas6 has not yet been extensively evaluated in clinical trials focused specifically on dry AMD. Extrapolating efficacy from animal models to human patients may encounter challenges due to differences in retinal architecture, immune responses, and disease heterogeneity. Early-phase clinical studies will be needed to validate safety and to confirm that the robust efficacy seen in preclinical models translates to human retinal tissue (ClinicalTrials.gov, n.d.).

• Delivery and Pharmacokinetics:
As a recombinant protein, Gas6 must be delivered in a manner that ensures its stability, persistence, and targeted delivery to RPE cells. Subretinal or intravitreal injection are the most likely routes; however, these methods have inherent technical challenges related to the invasiveness of the procedure, the potential for immunogenicity, and issues with achieving sustained therapeutic levels in the eye. Optimizing the formulation, dose frequency, and delivery devices will be critical to overcome these barriers (King Khaled Eye Specialist Hospital, 2011).

• Long-term Safety and Immunogenicity:
Protein therapeutics are associated with potential risks including the generation of anti-drug antibodies, which can reduce efficacy or trigger adverse immune responses. Long-term ocular safety data, particularly in the context of repeated dosing, will be essential to ensuring that recombinant Gas6 does not inadvertently induce local inflammation or toxicity in the sensitive retinal environment.

• Complexity of Dry AMD Pathogenesis:
Dry AMD is a multifactorial disorder with contributions from oxidative stress, complement dysregulation, genetic predispositions, and metabolic imbalances. While enhancing RPE phagocytosis and suppressing inflammation addresses two key aspects of the disease, it remains to be determined whether modulating a single signaling pathway will yield sufficient therapeutic benefit on its own. There is a strong case for considering recombinant human Gas6 as part of a broader combinatorial approach to dry AMD.

• Manufacturing and Regulatory Considerations:
The production of a biologic such as recombinant human Gas6 requires adherence to strict manufacturing controls to ensure bioactivity and reproducibility. Regulatory pathways for new ocular biologics can be complex, requiring extensive preclinical toxicology studies and robust clinical proof of concept before approval, particularly in a disease area with no current approved treatments for the dry form.

Overall, recombinant human Gas6 represents a strong candidate for further exploration as a therapeutic intervention for dry AMD. Its mechanism of action is well supported by both genetic and biochemical studies, and its ability to enhance LC3-associated phagocytosis combined with anti-inflammatory signaling directly addresses central aspects of RPE dysfunction in this disease. In vitro data showing substantial improvements in MerTK phosphorylation and POS uptake, along with promising preclinical animal model findings, provide a solid rationale for advancing this candidate into early-phase clinical studies. Nevertheless, the challenges associated with protein delivery, long-term safety, and the complex pathogenesis of dry AMD suggest that additional optimization and combination strategies may ultimately be necessary for maximal therapeutic benefit.

In conclusion, recombinant human Gas6 leverages a highly promising endogenous pathway—namely, the Gas6/MerTK signaling axis—to restore RPE phagocytic function and modulate inflammatory responses that are critically impaired in dry AMD. Its biologically defined mechanism, strong preclinical efficacy data as demonstrated by improvements in MerTK phosphorylation and photoreceptor outer segment clearance, and potential to shift the ocular cytokine milieu toward a reparative state make it a candidate of significant interest for further development. However, the success of this approach will depend on overcoming delivery challenges, establishing a favorable safety profile in the ocular setting, and integrating this intervention into a broader therapeutic strategy that addresses the multifactorial nature of dry AMD. Given the dearth of effective treatments for the dry form of AMD and the clear need for therapies that can preserve vision and retinal integrity, the further investigation of recombinant human Gas6 is both scientifically and clinically justified (Yefimova et al., 2021, pp. 13–15, 21–23; Singh, 2013, pp. 37–40; King Khaled Eye Specialist Hospital, 2011; ClinicalTrials.gov, n.d.).

References
ClinicalTrials.gov. (n.d.). Clinical trials search: Gas6 OR MerTK OR Tyro3 OR recombinant human Gas6 AND macular degeneration OR retinal degenerative disease. https://clinicaltrials.gov/

King Khaled Eye Specialist Hospital. (2011). Trial of subretinal injection of (rAAV2-VMD2-hMERTK) [Clinical trial registration NCT01482195]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01482195

Singh, A. K. (2013). The potential of human adipose tissue derived mesenchymal stem cells in cell therapy for retinal degenerative diseases (Doctoral dissertation). Universidad de Valladolid. https://doi.org/10.35376/10324/4380

Yefimova, M. G., Ravel, C., Rolland, A. D., Bourmeyster, N., & Jégou, B. (2021). Mertk-mediated LC3-associated phagocytosis (LAP) of apoptotic substrates in blood-separated tissues: Retina, testis, ovarian follicles. Cells, 10(6), 1443. https://doi.org/10.3390/cells10061443
